B7H3-targeting immune cell therapy for advanced solid tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called B7H3 on solid tumors. It is for people with advanced ovarian or peritoneal cancer who have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Standard cancer treatments have not worked for you.
- Your tumor has a specific protein called B7H3 on it (a lab test can show this).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, and kidney function are within certain limits.
- You agree to use birth control during treatment and for one year after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have a specific protein (B7-H3). The goal is to see if these modified immune cells can shrink tumors or slow their growth.
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
This Phase 1/2 study tests a personalized immune-cell treatment (fully human B7H3 CAR-T) for ovarian cancer that has come back or did not respond. It aims to see whether CAR-T can attack tumors that carry a target called B7H3.
This trial tests a new type of immune cell therapy called CAR T cells that target a protein called B7-H3 found on many solid tumors. It is for children and young adults whose cancer has come back or stopped responding to standard treatments.
This trial tests a special immune cell therapy (CAR T cells) that targets a protein called B7-H3 on your cancer cells. It is for people with small cell lung cancer or similar neuroendocrine cancers that have returned or not responded to standard treatments.
This trial tests a new treatment where your own immune cells are modified to attack ovarian cancer cells that have stopped responding to platinum chemotherapy. It's for people with recurrent ovarian cancer that hasn't gotten better with standard treatments.
Hear when a new Peritoneal (Metastatic) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.